News | Angiography | April 06, 2022

Dixon GRE Technique Outperforms Clinical Standard for Unenhanced Coronary MRA

Study included 44 patients with intermediate-to-high risk of coronary artery disease who underwent both 1.5-T SSFP and 3-T Dixon GRE coronary MRA examinations before coronary angiography.

According to ARRS’ American Journal of Roentgenology (AJR), the 3-T Dixon gradient-recalled echo (GRE) sequence performed higher than the current standard of 1.5-T SSFP for unenhanced coronary MRA, which could help expand clinical adoption of the procedure.

A 60-year-old man with chest pain. (A) Image from coronary angiogram shows no significant stenosis of right coronary artery (RCA). (B) Curved multiplanar reformatted image from 1.5-T SSFP coronary MRA shows severe stenosis of mid RCA (arrow), representing a false-positive finding. (C) Curved multiplanar reformatted image from 3-T Dixon GRE coronary MRA shows no RCA stenosis.


April 6, 2022 – According to ARRS’ American Journal of Roentgenology (AJR), the 3-T Dixon gradient-recalled echo (GRE) sequence performed higher than the current standard of 1.5-T SSFP for unenhanced coronary MRA, which could help expand clinical adoption of the procedure.

“For unenhanced coronary MRA, 3-T unenhanced Dixon GRE had better image quality and diagnostic performance than 1.5-T SSFP, particularly for distal and branch segments,” wrote lead researcher Hang Jin from China’s Fudan University and Shanghai Institute of Medical Imaging.

Jin and team’s prospective study included 44 patients (27 men, 17 women; mean age, 59 years) with intermediate-to-high risk of coronary artery disease who underwent both 1.5-T SSFP and 3-T Dixon GRE coronary MRA examinations before coronary angiography. Two radiologists independently assessed coronary arteries in random order for subjective image quality, number of visible segments, apparent contrast-to-noise ratio, and presence of significant stenoses.

Compared with 1.5-T SSFP, coronary MRA using 3-T unenhanced Dixon GRE demonstrated higher image quality (4.0±1.1 vs 3.0±1.2), higher percentage of visible coronary segments (96.7% vs 88.9%), as well as higher sensitivity (87.9% vs 77.3%) and specificity (83.3% vs 60.6%) for significant stenoses on a per-vessel basis, using coronary angiography as reference.

“The present results demonstrate the benefits of robust epicardial fat suppression using Dixon GRE in terms of improved apparent contrast-to-noise and improved visibility, with the latter difference observed particularly for distal and branch segments that course close to the myocardium,” the authors of this AJR article concluded.

Reference:

Unenhanced Whole-Heart Coronary MRA: Prospective Intraindividual Comparison of 1.5-T SSFP and 3-T Dixon Water-Fat Separation GRE Methods Using Coronary Angiography as Reference
 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now